Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108563 · ClinicalTrials.gov registry record · Phase 4
VISN 20: Prophylactic Treatment of Interferon-Induced Depression in Hepatitis C Patients
A Phase 4 study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 4
- Development phase
NCT00108563 is a Phase 4 study that has completed, run by US Department of Veterans Affairs.
The verdict
NCT00108563, a Phase 4 study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 4
- Development phase
Study Summary
The purpose of this study is to learn more about the effects of interferon and ribavirin combination therapy in people with Hepatitis C. The specific aims are: * To assess how often depressive symptoms occur in patients taking combination alpha interferon plus ribavirin or pegylated interferon plus ribavirin therapy for Hepatitis C, when depressive symptoms occur, and how severe the depressive symptoms are when they do occur; * To identify potential predictors for the development of depressive symptoms; * To identify if citalopram, an antidepressant medication, can prevent or lessen the severity of depressive symptoms brought about by interferon therapy.
Interventions
- DRUG Citalopram or Placebo
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-10 |
| Est. Completion | 2006-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00108563
The ClinicalTrials.gov registry entry for NCT00108563 describes a study currently listed as completed, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Citalopram or Placebo is the first listed.
NCT00108563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00108563 about?
NCT00108563 is a clinical study titled "VISN 20: Prophylactic Treatment of Interferon-Induced Depression in Hepatitis C Patients". The purpose of this study is to learn more about the effects of interferon and ribavirin combination therapy in people with Hepatitis C. The specific aims are: * To assess how often depressive symptoms occur in patients taking combination alpha interferon plus ribavirin or pegylated interferon plus...
What is the current status of trial NCT00108563?
This trial is currently completed. It is a Phase 4 study. The study started on 2003-10. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00108563?
The interventions under investigation include: Citalopram or Placebo (DRUG).
Who is sponsoring clinical trial NCT00108563?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.